Russia fund in consortium to back U.S. pharma firms
20 December 2012
Russian state technology firm Rusnano, alongside a group of investors, is investing $93 million in three U.S.-based pharmaceutical firms to develop drugs to treat illnesses such as epilepsy, the investors said on Wednesday.
Decentralized clinical trials, patient experience and the role of supply chain management
05 July 2022
Pharma can no longer rely on traditional sales and marketing to launch new drugs: report
05 July 2022
The Ministry of Industry and Trade has amended the draft document on the “second one out” rule
04 July 2022
A project on remote sale of prescription drugs has been presented
04 July 2022